The DOI matches its Crossref record; 420 of the 420 references it cites were found in a registry or an index.
Natural product and natural product derived drugs in clinical trials
Abstract
The 25 Natural Product (NP)-derived drugs launched since 2008 and the 100 NP-derived compounds and 33 Antibody Drug Conjugates (ADCs) in clinical trials or in registration at the end of 2013 are reviewed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–400 of 420
In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00
Joshi, K., Rathos, M. J., Joshi, R., Sivakumar, M., Mascarenhas, M., Kamble, S., Lal, B., & Sharma, S. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0613 · Cited by 121
The structure of nojirimycin, a piperidinose sugar antibiotic.
Inouye, S., Tsuruoka, T., & Nida, T. (1966) · PubMed · Cited by 120
Crowther, G. S., Baines, S. D., Todhunter, S. L., Freeman, J., Chilton, C. H., & Wilcox, M. H. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks359 · Cited by 120
From micrograms to grams: scale-up synthesis of eribulin mesylate
Yu, M. J., Zheng, W., & Seletsky, B. M. (2013) · Natural Product Reports · doi:10.1039/c3np70051h · Cited by 120
Belley, A. C., McKay, G. A., Arhin, F. F., Sarmiento, I., Beaulieu, S., Fadhil, I., Parr, T. R., & Moeck, G. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00760-10 · Cited by 120
Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia
Gandhi, V., Plunkett, W., & Cortes, J. E. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1283 · Cited by 118
Webster, L. R., Dhar, S., Eldon, M. A., Masuoka, L. K., Lappalainen, J., & Sostek, M. B. (2013) · Pain · doi:10.1016/j.pain.2013.04.024 · Cited by 117
Discovery of LFF571: An Investigational Agent for Clostridium difficile Infection
LaMarche, M. J., Leeds, J. A., Amaral, A., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201685h · Cited by 116
Mullard, A. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4239 · Cited by 116
Isolation and First Total Synthesis of PM050489 and PM060184, Two New Marine Anticancer Compounds
Martín, M. J., Coello, L., Fernández, R., Reyes, F., Rodríguez, A., Murcia, C., Garranzo, M., Mateo, C., Sánchez-Sancho, F., Bueno, S., et al. (2013) · Journal of the American Chemical Society · doi:10.1021/ja404578u · Cited by 114
Sinha, S., Du, Z., Maiti, P., Klärner, F., Schrader, T. H., Wang, C., & Bitan, G. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn200133x · Cited by 113
(-)-Cytisine and derivatives: synthesis, reactivity, and applications.
Rouden, J., Lasne, M., Blanchet, J., & Baudoux, J. (2014) · Chemical Reviews · doi:10.1021/cr400307e · Cited by 113
Targeting mTOR Pathways in Human Malignancies
Fasolo, A., & Sessa, C. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212800626210 · Cited by 112
Ojima, I., Slater, J. C., Kuduk, S. D., Takeuchi, C. S., Gimi, R. H., Sun, C., Park, Y. H., Pera, P. J., Veith, J. M., & Bernacki, R. J. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm960563e · Cited by 112
Cisternino, S., Bourasset, F., Archimbaud, Y., Sémiond, D., Sanderink, G., & Scherrmann, J. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705150 · Cited by 111
Marine natural products: Bryostatins in preclinical and clinical studies
Kollár, P., Rajchard, J., Balounová, Z., & Pazourek, J. (2013) · Pharmaceutical Biology · doi:10.3109/13880209.2013.804100 · Cited by 110
HATANAKA, H., KINO, T., Miyata, S., Inamura, N., KURODA, A., Goto, T., Tanaka, H., & OKUHARA, M. (1988) · The Journal of Antibiotics · doi:10.7164/antibiotics.41.1592 · Cited by 110
Vidal, A., Muñoz, C., Guillén, M.-J., Moretó, J., Puertas, S., Martínez‐Iniesta, M., Figueras, A., Padullés, L., García-Rodríguez, F. J., Berdiel‐Acer, M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1513 · Cited by 108
Möhrle, J. J., Duparc, S., Siethoff, C., van Giersbergen, P. L. M., Craft, J. C., Arbe‐Barnes, S., Charman, S. A., Gutierrez, M., Wittlin, S., & Vennerstrom, J. L. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04368.x · Cited by 107
Combating evolution with intelligent design: the neoglycoside ACHN-490
Armstrong, E. S., & Miller, G. H. (2010) · Current Opinion in Microbiology · doi:10.1016/j.mib.2010.09.004 · Cited by 107
The structure of rohitukine, the main alkaloid of (Syn. ) (meliaceae)
Harmon, A. D., Weiß, U., & Silverton, J. V. (1979) · Tetrahedron Letters · doi:10.1016/s0040-4039(01)93556-7 · Cited by 107
Apple Trees to Sodium Glucose Co-Transporter Inhibitors: A Review of SGLT2 Inhibition
White, J. R. (2010) · Clinical Diabetes · doi:10.2337/diaclin.28.1.5 · Cited by 106
A Novel Macrolide Solithromycin Exerts Superior Anti-inflammatory Effect via NF-κB Inhibition
Kobayashi, Y., Wada, H., Rossios, C., Takagi, D., Higaki, M., Mikura, S., Goto, H., Barnes, P. J., & Ito, K. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.200733 · Cited by 103
Fidaxomicin Is an Inhibitor of the Initiation of Bacterial RNA Synthesis
Artsimovitch, I., Seddon, J., & Sears, P. S. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis358 · Cited by 103
Current strategies for drug discovery through natural products
Harvey, A. L., Clark, R. L., Mackay, S. P., & Johnston, B. F. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2010.488263 · Cited by 102
Polyphenon E® : a new treatment for external anogenital warts
Tatti, S., Stockfleth, E., Beutner, K. R., Tawfik, H., Elsasser, U., Weyrauch, P., & Mescheder, A. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09375.x · Cited by 102
N -Chloramines, a Promising Class of Well-Tolerated Topical Anti-Infectives
Gottardi, W., Debabov, D. V., & Nagl, M. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02132-12 · Cited by 101
Polymer–drug conjugates: present state of play and future perspectives
Pang, X., Du, H., Zhang, H.-Q., Zhai, Y., & Zhai, G. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.09.007 · Cited by 101
Coronelli, C., White, R. J., Lancini, G., & PARENTI, F. (1975) · The Journal of Antibiotics · doi:10.7164/antibiotics.28.253 · Cited by 101
Benjamin, E. R., Khanna, R., Schilling, A. E., Flanagan, J. J., Pellegrino, L. J., Brignol, N., Lun, Y., Guillen, D., Ranes, B. E., Frascella, M., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.271 · Cited by 101
Pfaller, M. A., Messer, S. A., Motyl, M. R., Jones, R. N., & Castanheira, M. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks466 · Cited by 100
Investigational Antimicrobial Agents of 2013
Pucci, M. J., & Bush, K. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00033-13 · Cited by 100
Actinonin: an Antibiotic Substance produced by an Actinomycete
Gordon, J. J., KELLY, B. K., & MILLER, G. A. (1962) · Nature · doi:10.1038/195701b0 · Cited by 99
Pfaller, M. A., Messer, S. A., Motyl, M. R., Jones, R. N., & Castanheira, M. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01588-12 · Cited by 98
α-Tocotrienol quinone modulates oxidative stress response and the biochemistry of aging
Shrader, W. D., Amagata, A., Barnes, A. J., Enns, G. M., Hinman, A., Jankowski, O. D., Kheifets, V., Komatsuzaki, R., Lee, E., Mollard, P., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.04.085 · Cited by 98
Farrell, D. J., Robbins, M. J., Rhys‐Williams, W., & Love, W. G. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01285-10 · Cited by 98
The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics
Gerber, H., Koehn, F. E., & Abraham, R. T. (2013) · Natural Product Reports · doi:10.1039/c3np20113a · Cited by 97
Hagen, N. A., du Souich, P., Lapointe, B. J., Ong-Lam, M., Dubuc, B., Walde, D., Love, R., & Ngoc, A. H. (2008) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2007.05.011 · Cited by 96
Engel, J. B., Emons, G., Pinski, J., & Schally, A. V. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.685128 · Cited by 96
Lai, K., Huang, C.-K., Chang, Y., Chung, C., Yamashita, S., Li, L., Lee, S. O., Yeh, S., & Chang, C. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.10.029 · Cited by 96
D’Amore, C., Leva, F. S. D., Sepe, V., Renga, B., Gaudio, C. D., D’Auria, M. V., Zampella, A., Fiorucci, S., & Limongelli, V. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401873d · Cited by 96
Reichert, J. M. (2013) · mAbs · doi:10.4161/mabs.27333 · Cited by 96
Bleiholder, C., Do, T. D., Wu, C. F., Economou, N. J., Bernstein, S. L., Buratto, S. K., Shea, J., & Bowers, M. T. (2013) · Journal of the American Chemical Society · doi:10.1021/ja406197f · Cited by 95
GSK3 Alpha and Beta Are New Functionally Relevant Targets of Tivantinib in Lung Cancer Cells
Rix, L. L. R., Kuenzi, B. M., Luo, Y., Remily-Wood, E. R., Kinose, F., Wright, G. M., Li, J., Koomen, J. M., Haura, E. B., Lawrence, H. R., et al. (2013) · ACS Chemical Biology · doi:10.1021/cb400660a · Cited by 93
Isolation and structure of a hoplonemertine toxin
Kem, W. R., ABBOTT, B. C., & Coates, R. M. (1971) · Toxicon · doi:10.1016/0041-0101(71)90039-0 · Cited by 93
Design of Antibody−Maytansinoid Conjugates Allows for Efficient Detoxification via Liver Metabolism
Sun, X., Widdison, W. C., Mayo, M., Wilhelm, S. D., Leece, B. A., Chari, R. V. J., Singh, R., & Erickson, H. K. (2011) · Bioconjugate Chemistry · doi:10.1021/bc100498q · Cited by 93
Bissonnette, R., Poulin, Y., Zhou, Y., Tan, J., Hong, H. C., Webster, J., Ip, W., Tang, L., & Lyle, M. (2012) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2011.10775.x · Cited by 92
XF-73, a novel antistaphylococcal membrane-active agent with rapid bactericidal activity
Ooi, N., Miller, K., Hobbs, J. K., Rhys‐Williams, W., Love, W. C., & Chopra, I. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp299 · Cited by 92
Expanding medicinal chemistry space
Barker, A. J., Kettle, J. G., Nowak, T., & Pease, J. E. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.10.008 · Cited by 91
Ocio, E. M., Maiso, P., Chen, X., Garayoa, M., Álvarez-Fernández, S., San‐Segundo, L., Vilanova, D., López‐Corral, L., Montero, J. C., Hernández‐Iglesias, T., et al. (2008) · Blood · doi:10.1182/blood-2008-09-177774 · Cited by 90
scyllo-Inositol, Preclinical, and Clinical Data for Alzheimer’s Disease
Ma, K., Thomason, L. A. M., & McLaurin, J. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-394816-8.00006-4 · Cited by 89
Wang, X., Dong, Y., Wittlin, S., Charman, S. A., Chiu, F. C. K., Chollet, J., Katneni, K., Mannila, J., Morizzi, J., Ryan, E., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400004u · Cited by 89
Fitzgerald, D. P., Emerson, D. L., Qian, Y., Anwar, T., Liewehr, D. J., Steinberg, S. M., Silberman, S., Palmieri, D., & Steeg, P. S. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0061 · Cited by 89
Lestaurtinib, a multitargeted tyrosinse kinase inhibitor: from bench to bedside
Shabbir, M., & Stuart, R. K. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543781003598862 · Cited by 89
Tiacumicins, a novel complex of 18-membered macrolides. II. Isolation and structure determination.
Hochlowski, J. E., Swanson, S., RANFRANZ, L. M., Whittern, D. N., BUKO, A. M., & McAlpine, J. B. (1987) · The Journal of Antibiotics · doi:10.7164/antibiotics.40.575 · Cited by 88
Antibiotic GE2270 A: A novel inhibitor of bacterial protein synthesis. II. Structure elucidation.
KETTENRING, J., Colombo, L., Ferrari, P., Tavecchia, P., Nebuloni, M., VÉREY, K., Gallo, G. G., & Selva, E. (1991) · The Journal of Antibiotics · doi:10.7164/antibiotics.44.702 · Cited by 87
New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer
van Hattum, A. H., Pinedo, H. M., Schlüper, H. M. M., Hausheer, F. H., & Boven, E. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20001015)88:2<260::aid-ijc18>3.0.co;2-q · Cited by 86
Khanna, R., Flanagan, J. J., Feng, J., Soska, R., Frascella, M., Pellegrino, L. J., Lun, Y., Guillen, D., Lockhart, D. J., & Valenzano, K. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040776 · Cited by 86
Toki, B. E., Cerveny, C. G., Wahl, A. F., & Senter, P. D. (2002) · The Journal of Organic Chemistry · doi:10.1021/jo016187+ · Cited by 86
From natural product to marketed drug: the tiacumicin odyssey
Erb, W., & Zhu, J. (2012) · Natural Product Reports · doi:10.1039/c2np20080e · Cited by 86
Noel, G. J., Draper, M. P., Hait, H. I., Tanaka, S. K., & Arbeit, R. D. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00948-12 · Cited by 86
Ellis, D., Usman, M. H., Milner, P. G., Canafax, D. M., & Ezekowitz, M. D. (2009) · Circulation · doi:10.1161/circulationaha.109.856120 · Cited by 85
Iizawa, Y., Nagai, J., Ishikawa, T., Hashiguchi, S., Nαkαo, M., Miyake, A., & Okonogi, K. (2004) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-004-0309-3 · Cited by 85
Kato, K., Shirasaka, Y., Kuraoka, E., Kikuchi, A., Iguchi, M., Suzuki, H., Shibasaki, S., Kurosawa, T., & Tamai, I. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100130b · Cited by 84
Paukner, S., Sader, H. S., Ivezic‐Schoenfeld, Z., & Jones, R. N. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00358-13 · Cited by 84
Resveratrol: From Basic Studies to Bedside
Borriello, A., Bencivenga, D., Caldarelli, I., Tramontano, A., Borgia, A., Zappia, V., & Ragione, F. D. (2013) · Cancer treatment and research · doi:10.1007/978-3-642-38007-5_10 · Cited by 82
Li, L., Shukla, S., Lee, A., Garfield, S. H., Maloney, D. J., Ambudkar, S. V., & Yuspa, S. H. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4303 · Cited by 81
Gualberto, A. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.641532 · Cited by 81
Dobbins, R. L., O’Connor‐Semmes, R., Kapur, A., Kapitza, C., Golor, G., Mikoshiba, I., Tao, W., & Hussey, E. K. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01462.x · Cited by 80
Zang, Y., Thomas, S. M., Chan, E. T., Kirk, C. J., Freilino, M. L., DeLancey, H. M., Grandis, J. R., Li, C., & Johnson, D. E. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1213 · Cited by 80
Zhang, W., Welihinda, A. A., Mechanic, J., Ding, H., Zhu, L., Lu, Y., Deng, Z., Sheng, Z., Lv, B., Chen, Y., et al. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.01.001 · Cited by 79
Mascio, C. T. M., Mortin, L. I., Howland, K., Praagh, A. D. G. V., Zhang, S., Arya, A., Chuong, C. L., Kang, C., Li, T., & Silverman, J. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00057-12 · Cited by 79
Rahman, K. M., Thompson, A. S., James, C., Narayanaswamy, M., & Thurston, D. E. (2009) · Journal of the American Chemical Society · doi:10.1021/ja902986x · Cited by 78
Anderson, P. M., Meyers, P. A., Kleinerman, E. S., Venkatakrishnan, K., Hughes, D. P. M., Herzog, C. E., Huh, W. W., Sutphin, R. M., Vyas, Y. M., Shen, V., et al. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24686 · Cited by 77
Mechanism of Antimalarial Action of the Synthetic Trioxolane RBX11160 (OZ277)
Uhlemann, A., Wittlin, S., Matile, H., Bustamante, L. Y., & Krishna, S. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01064-06 · Cited by 77
Saravolatz, L. D., Pawlak, J., Johnson, L., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00194-12 · Cited by 76
Bertrand, D., Bertrand, S., Neveu, E., & FERNANDES, P. B. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00840-10 · Cited by 76
Novel antifungal agents: a patent review (2011 – present)
Castelli, M. V., Butassi, E., Monteiro, M. C., Svetaz, L. A., Vicente, F., & Zacchino, S. A. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.876993 · Cited by 76
Patterson, D. M., Zweifel, M., Middleton, M. R., Price, P., Folkes, L. K., Stratford, M. R. L., Ross, P., Halford, S. E. R., Peters, J., Balkissoon, J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2414 · Cited by 76
Fiorucci, S., Cipriani, S., Mencarelli, A., Baldelli, F., Bifulco, G., & Zampella, A. (2011) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955711796355258 · Cited by 76
Qutenza®: a capsaicin 8% patch for the management of postherpetic neuralgia
Wallace, M. S., & Pappagallo, M. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.182 · Cited by 76
Pérez, E. G., Méndez‐Gálvez, C., & Cassels, B. K. (2012) · Natural Product Reports · doi:10.1039/c2np00100d · Cited by 75
Fluorocyclines. 2. Optimization of the C-9 Side-Chain for Antibacterial Activity and Oral Efficacy
Clark, R. B., Hunt, D. K., He, M., Achorn, C., Chen, C.-L., Deng, Y., Fyfe, C., Grossman, T. H., Hogan, P. C., O’Brien, W. J., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm201467r · Cited by 74
Coe, J. W., Brooks, P. R., Wirtz, M. C., Bashore, C. G., Bianco, K. E., Vetelino, M. G., Arnold, E. P., Lebel, L. A., Fox, C. B., Tingley, F. D., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.08.035 · Cited by 73
Utz, I., Hofer, S., Regenass, U., Hilbe, W., Thaler, J., Grunicke, H., & Hofmann, J. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910570119 · Cited by 72
Antibody–Drug Conjugate Payloads
Anderl, J., Faulstich, H., Hechler, T., & Kulke, M. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-541-5_4 · Cited by 72
Kem, W. R., Soti, F. S., Wildeboer, K. M., LeFrancois, S., MacDougall, K., Wei, D., Chou, K., & Arias, H. R. (2006) · Marine Drugs · doi:10.3390/md403255 · Cited by 72
Fogler, W. E., Wade, R. E., BRUNDISH, D. E., & Fidler, I. J. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.135.2.1372 · Cited by 71
The transcription inhibitor lipiarmycin blocks DNA fitting into the RNA polymerase catalytic site
Tupin, A., Gualtiéri, M., Léonetti, J., & Brodolin, K. L. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.135 · Cited by 71
Cyclin-Dependent Kinase Modulators and Cancer Therapy
Gallorini, M., Cataldi, A., & di Giacomo, V. (2012) · BioDrugs · doi:10.1007/bf03261895 · Cited by 71
Folate–Vinca Alkaloid Conjugates for Cancer Therapy: A Structure–Activity Relationship
Leamon, C. P., Vlahov, I. R., Reddy, J. A., Vetzel, M., Santhapuram, H. K. R., You, F., Bloomfield, A., Dorton, R., Nelson, M., Kleindl, P. J., et al. (2014) · Bioconjugate Chemistry · doi:10.1021/bc400441s · Cited by 70
Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3
Tapper, E. B., & Afdhal, N. H. (2013) · Journal of Viral Hepatitis · doi:10.1111/jvh.12168 · Cited by 70
Hughes, T. E., Kim, D. D., Marjason, J. K., Proietto, J., Whitehead, J. P., & Vath, J. E. (2013) · Obesity · doi:10.1002/oby.20356 · Cited by 69
Williams, C. B., Kambhampati, S., Fiskus, W. C., Wick, J., Dutreix, C., Ganguly, S., Aljitawi, O. S., Reyes, R., Fleming, A., Abhyankar, S., et al. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1316 · Cited by 68
Wu, J., Clingen, P. H., Spanswick, V. J., Mellinas‐Gomez, M., Meyer, T., Puzanov, I. J., Jodrell, D. I., Hochhauser, D., & Hartley, J. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2529 · Cited by 68
Semi-synthetic glycopeptide antibacterials
Judice, J. K., & Pace, J. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.08.067 · Cited by 68
New and Emerging Drug Molecules Against Obesity
George, M., Rajaram, M., & Shanmugam, E. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413501017 · Cited by 68
Cesare, M. D., Pratesi, G., Perego, P., Carenini, N., Tinelli, S., Merlini, L., Penco, S., Pisano, C., Bucci, F., Vesci, L., et al. (2001) · PubMed · Cited by 68
Novel Anti-Prostate Cancer Curcumin Analogues That Enhance Androgen Receptor Degradation Activity
Shi, Q., Shih, C. C.-Y., & Lee, K. H. (2009) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152009789124655 · Cited by 68
Resveratrol in the management of human cancer: how strong is the clinical evidence?
Gescher, A. J., Steward, W. P., & Brown, K. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12205 · Cited by 67
Molecular Targets of FTY720 (Fingolimod)
Pitman, M. R., Woodcock, J. M., Lopez, A. F., & Pitson, S. M. (2012) · Current Molecular Medicine · doi:10.2174/156652412803833599 · Cited by 67
Pharmacological chaperone therapy for Fabry disease
ISHII, S. (2012) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.88.18 · Cited by 66
Barbour, A., Schmidt, S., Rand, K. H., & Derendorf, H. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.12.012 · Cited by 64
Yuan, C., & Israel, R. J. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.5.541 · Cited by 64
The Cyclophilin Inhibitor SCY-635 Disrupts Hepatitis C Virus NS5A-Cyclophilin A Complexes
Hopkins, S., Bobardt, M. D., Chatterji, U., Garcia-Rivera, J. A., Lim, P. J., & Gallay, P. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00693-12 · Cited by 64
Romano, M., Frapolli, R., Zangarini, M., Bello, E., Porcu, L., Galmarini, C. M., García‐Fernández, L., Cuevas, C., Allavena, P., Erba, E., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28213 · Cited by 63
The Chemistry and Biology of the Bryostatins: Potential PKC Inhibitors in Clinical Development
Ruan, B., & Zhu, H. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712800493020 · Cited by 62
Bowles, D. W., Ma, W. W., Senzer, N. N., Brahmer, J. R., Adjei, A. A., Davies, M. A., Lazar, A. J., Vo, A. C. H., Peterson, S., Walker, L. N., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.474 · Cited by 62
Schwartz, R. E., Smith, S. K., Onishi, J. C., Meinz, M. S., Kurtz, M. B., GIACOBBE, R. A., Wilson, K. E., Liesch, J. M., Zink, D. L., Horn, W. S., et al. (2000) · Journal of the American Chemical Society · doi:10.1021/ja9944296 · Cited by 61
Pera, B., Barasoaín, I., Pantazopoulou, A., Canales, Á., Matesanz, R., Rodríguez‐Salarichs, J., García‐Fernández, L., Moneo, V., Jiménez‐Barbero, J., Galmarini, C. M., et al. (2013) · ACS Chemical Biology · doi:10.1021/cb400461j · Cited by 61
In Vivo and In Vitro Effects of SAR 943, a Rapamycin Analogue, on Airway Inflammation and Remodeling
Fujitani, Y., & Trifilieff, A. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200205-455oc · Cited by 61
Cozzi, S., Ogbourne, S. M., James, C., Rebel, H. G., de Gruijl, F. R., Ferguson, B., Gardner, J., Lee, T. T., Larcher, T., & Suhrbier, A. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.418 · Cited by 61
Rischin, D., Bibby, D. C., Chong, G., Kremmidiotis, G., Leske, A. F., Matthews, C. A., Wong, S., Rosen, M. A., & Desai, J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0937 · Cited by 61
Fügi, M. A., Wittlin, S., Dong, Y., & Vennerstrom, J. L. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01305-09 · Cited by 61
Leeds, J. A., Sachdeva, M., Mullin, S., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06354-11 · Cited by 58
Han, C. K., Ahn, S. K., Choi, N. S., Hong, R. K., Moon, S. K., Chun, H. S., Lee, S. J., Kim, J. W., Hong, C. I., Kim, D., et al. (2000) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(99)00577-6 · Cited by 58
Citron, D. M., Tyrrell, K. L., Merriam, C. V., & Goldstein, E. J. C. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06305-11 · Cited by 57
Martínez, M., Guillen-Navarro, M. J., Pera, B., Bouchet, B. P., Martínez-Leal, J. F., Barasoaı́n, I., Cuevas, C., Andreu, J. M., García‐Fernández, L., Díaz, J. F., et al. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.026 · Cited by 56
Citron, D. M., Tyrrell, K. L., Merriam, C. V., & Goldstein, E. J. C. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05655-11 · Cited by 56
HOME TREATMENT OF SKIN CANCER AND SOLAR KERATOSES
Green, A. C., & Beardmore, G. L. (1988) · Australasian Journal of Dermatology · doi:10.1111/j.1440-0960.1988.tb00383.x · Cited by 55
Serruys, P. W. J. C., Garg, S., Abizaid, A., Ormiston, J., Windecker, S., Verheye, S., Dubois, C., Stewart, J. T., Hauptmann, K. E., Schöfer, J., et al. (2010) · EuroIntervention · doi:10.4244/eijv6i2a32 · Cited by 55
Transient receptor potential vanilloid 1 as a therapeutic target in analgesia
Szolcsányi, J., & Pintér, E. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.772580 · Cited by 54
Nowak, A. K., Brown, C. S. B., Millward, M., Creaney, J., Byrne, M., Hughes, B. G. M., Kremmidiotis, G., Bibby, D. C., Leske, A. F., Mitchell, P. L. R., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.05.006 · Cited by 54
Ekman, S., Frödin, J., Harmenberg, J., Bergman, A., Hedlund, Å., Dahg, P., Alvfors, C., Ståhl, B., Bergström, S. N., & Bergqvist, M. (2010) · Acta Oncologica · doi:10.3109/0284186x.2010.499370 · Cited by 54
MacArthur, R. D., Hawkins, T., Brown, S. J., LaMarca, A., Clay, P. G., Barrett, A. C., Bortey, E. B., Paterson, C. A., Golden, P. L., & Forbes, W. P. (2013) · HIV Clinical Trials · doi:10.1310/hct1406-261 · Cited by 53
Kuglstatter, A., Mueller, F., Kusznir, E. A., Gsell, B., Stihle, M., Thoma, R., Benz, J., Aspeslet, L. J., Freitag, D. G., & Hennig, M. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910051905 · Cited by 53
Snydman, D. R., Jacobus, N. V., & McDermott, L. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06257-11 · Cited by 52
Kapur, A., O'Connor‐Semmes, R. L., Hussey, E. K., Dobbins, R. L., Tao, W. X., Hompesch, M., Smith, G. A., Polli, J. W., James, C. D., Mikoshiba, I., et al. (2013) · BMC Pharmacology and Toxicology · doi:10.1186/2050-6511-14-26 · Cited by 51
Chiba, K., & Adachi, K. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.25 · Cited by 51
Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist
Nishi, T., Miyazaki, S., Takemoto, T., Suzuki, K., Iio, Y., Nakajima, K., Ohnuki, T., Kawase, Y., Nara, F., Inaba, S., et al. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml100301k · Cited by 51
Quadri, L., Bianchi, G., Cerri, A., et al. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm970162e · Cited by 50
Bauer, S., Hilger, R. A., Mühlenberg, T., Grabellus, F., Nagarajah, J., Hoiczyk, M., Reichardt, A., Ahrens, M., Reichardt, P., Grünewald, S., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.826 · Cited by 50
The use of sinecatechins (polyphenon E) ointment for treatment of external genital warts
Stockfleth, E., & Meyer, T. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.676036 · Cited by 50
FDA rejects novel diabetes drug over safety fears
Burki, T. K. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60216-5 · Cited by 49
Minnelide: A Novel Therapeutic That Promotes Apoptosis in Non-Small Cell Lung Carcinoma In Vivo
Roušalová, I., Banerjee, S., Sangwan, V., Evenson, K., McCauley, J. A., Kratzke, R. A., Vickers, S. M., Saluja, A. K., & D’Cunha, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077411 · Cited by 48
Tubulin-Targeted Agents Including Docetaxel and Cabazitaxel
Cheetham, P. J., & Petrylak, D. P. (2013) · The Cancer Journal · doi:10.1097/ppo.0b013e3182828d38 · Cited by 48
Rodgers, W., Frazier, A. D., & Champney, W. S. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02316-12 · Cited by 48
The year's new drugs & biologics - 2009
Graul, A. I., Sorbera, L. A., Pina, P., Tell, M., Cruces, E., Rosa, E., Stringer, M., Castaner, R. M., & Revel, L. (2010) · Drug News & Perspectives · doi:10.1358/dnp.2010.23.1.1440373 · Cited by 48
Trabectedin and Plitidepsin: Drugs from the Sea that Strike the Tumor Microenvironment
Galmarini, C. M., D’Incalci, M., & Allavena, P. (2014) · Marine Drugs · doi:10.3390/md12020719 · Cited by 47
Farrell, D. J., Robbins, M. J., Rhys‐Williams, W., & Love, W. G. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.02.008 · Cited by 47
Update on alisporivir in treatment of viral hepatitis C
Flisiak, R., Jaroszewicz, J., Flisiak, I., & Łapiński, T. W. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.658641 · Cited by 47
Proceedings of the First International Conference on PEP005
Ogbourne, S. M., Hampson, P., Lord, J. M., Parsons, P. G., de Witte, P. A. M., & Suhrbier, A. (2007) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3280149ec5 · Cited by 47
Yamada, M., Watanabe, T., Baba, N., Takeuchi, Y., Ohsawa, F., & Gomi, S. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01456-07 · Cited by 46
New horizons for host defense peptides and lantibiotics
Dawson, M. J., & Scott, R. W. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.06.006 · Cited by 45
Boakes, S., Appleyard, A. N., Cortés, J., & Dawson, M. J. (2010) · The Journal of Antibiotics · doi:10.1038/ja.2010.48 · Cited by 43
Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes
Lamos, E. M., Younk, L. M., & Davis, S. N. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.909407 · Cited by 43
Schnitzer, T. J., Pelletier, J., Haselwood, D. M., Ellison, W., Ervin, J. E., GORDON, R. D., LISSE, J. R., Archambault, W. T., Sampson, A. R., FEZATTE, H. B., et al. (2011) · The Journal of Rheumatology · doi:10.3899/jrheum.110192 · Cited by 42
Synthesis and opioid receptor binding properties of a highly potent 4-hydroxy analogue of naltrexone
Wentland, M. P., Lu, Q., Lou, R., Bu, Y., Knapp, B. I., & Bidlack, J. M. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.02.032 · Cited by 41
Gregson, S. J., Howard, P. W., Thurston, D. E., Jenkins, T. C., & Kèlland, L. R. (1999) · Chemical Communications · doi:10.1039/a809791g · Cited by 41
EC145: a novel targeted agent for adenocarcinoma of the lung
Pribble, P., & Edelman, M. J. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.671294 · Cited by 40
Hussey, E. K., Kapur, A., O'Connor‐Semmes, R. L., Tao, W. X., Rafferty, B., Polli, J. W., James, C. D., & Dobbins, R. L. (2013) · BMC Pharmacology and Toxicology · doi:10.1186/2050-6511-14-25 · Cited by 39
Lanaspa, M., Moraleda, C., Machevo, S., González, R., Serrano, B., Macete, E., Cisteró, P., Mayor, A. G., Hutchinson, D., Kremsner, P. G., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00018-12 · Cited by 39
Opioid modulators for alcohol dependence
Hillemacher, T., Heberlein, A., Muschler, M. A. N., Bleich, S., & Frieling, H. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.592139 · Cited by 39
Song, Y., Lunde, C. S., Benton, B. M., & Wilkinson, B. J. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05403-11 · Cited by 38
DA6034 promotes gastric epithelial cell migration and wound‐healing through the mTOR pathway
Kim, Y., Lee, W. H., Choi, S. M., Seo, Y. Y., Ahn, B. O., Kim, S. H., & Kim, S. G. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.06873.x · Cited by 38
Marfurt, J., Chalfein, F., Prayoga, P., Wabiser, F., Wirjanata, G., Sebayang, B. F., Piera, K. A., Wittlin, S., Haynes, R. K., Möhrle, J. J., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00283-12 · Cited by 38
Hu, K., Li, J., Wang, W., Wu, H., Lin, H., & WEBSTER, J. M. (1998) · Canadian Journal of Microbiology · doi:10.1139/w98-098 · Cited by 37
Cuypers, J., Mathieu, C., & Benhalima, K. (2013) · Acta Clinica Belgica · doi:10.2143/acb.3349 · Cited by 37
Pipeline of Known Chemical Classes of Antibiotics
Mendes, C. D. D. S., & Antunes, A. M. D. S. (2013) · Antibiotics · doi:10.3390/antibiotics2040500 · Cited by 37
Fluoride enhances the activity of fungicides that destabilize cell membranes
Li, S., & Breaker, R. R. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.03.006 · Cited by 36
Heasley, B. H., Pacofsky, G. J., Mamai, A., Liu, H., Nelson, K., Coti, G., Peel, M. R., Balkovec, J. M., Greenlee, M. L., Liberator, P., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.05.031 · Cited by 35
Generation of Novel Rapamycin Structures by Microbial Manipulations.
NLSHIDA, H., SAKAKIBARA, T., AOKI, F., Saito, T., Ichikawa, K., INAGAKI, T., Kojima, Y., YAMAUCHI, Y., HUANG, L. H., Guadliana, M., et al. (1995) · The Journal of Antibiotics · doi:10.7164/antibiotics.48.657 · Cited by 35
Lupi, A., Secco, G. G., Rognoni, A., Lazzero, M., Fattori, R., Sheiban, I., Bongo, A. S., Bolognese, L., Agostoni, P., & Porto, I. (2014) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.25416 · Cited by 34
Mascitti, V., Thuma, B. A., Smith, A. C. T., Robinson, R. P., Brandt, T. A., Kalgutkar, A. S. S., Maurer, T. S., Samas, B., & Sharma, R. (2012) · MedChemComm · doi:10.1039/c2md20163a · Cited by 34
New β-glucan inhibitors as antifungal drugs
Hector, R. F., & Bierer, D. E. (2011) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2011.603899 · Cited by 34
He, X., Koenen, H. J. P. M., Smeets, R. L., Keijsers, R., van Rijssen, E., Koerber, A., van de Kerkhof, P. C., Boots, A. M. H., & Joosten, I. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.459 · Cited by 33
Bronson, J. J., Dhar, T. G. M., Ewing, W. R., & Lönberg, N. (2012) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-396492-2.00031-x · Cited by 33
Ingenol mebutate: A new option for actinic keratosis treatment
Gras, J. (2013) · Drugs of today · doi:10.1358/dot.2013.49.1.1910723 · Cited by 32
Bojsen, R. K., Torbensen, R., Larsen, C. E., Folkesson, A., & Regenberg, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069483 · Cited by 32
Cyclophilin inhibitors as antiviral agents
Peel, M. R., & Scribner, A. W. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.05.101 · Cited by 32
Horn, W. D. V. (2013) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2013.791659 · Cited by 31
Irie, K., Yanagita, R. C., & Nakagawa, Y. (2010) · Medicinal Research Reviews · doi:10.1002/med.20220 · Cited by 31
Moberly, J. B., Ford, D. M., Zahir, H., Chen, S., Mochizuki, T., Truitt, K. E., & Vollmer, T. L. (2012) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2012.03.007 · Cited by 30
Methylnaltrexone for the treatment of opioid-induced constipation
Bader, S., Dürk, T., & Becker, G. (2012) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.12.63 · Cited by 30
Farrell, D. J., Flamm, R. K., Sader, H. S., & Jones, R. N. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.11.005 · Cited by 30
Financial Aspects and the Future of the Pharmaceutical Industry in the United States of America
Karamehić, J., Riđić, O., Riđić, G., Jukić, T., Ćorić, J., Subasic, D., Panjeta, M., Žunić, L., & Mašić, I. (2013) · Materia Socio Medica · doi:10.5455/msm.2013.25.286-290 · Cited by 28
Turning Glucosuria into a Therapy: Efficacy and Safety with SGLT2 Inhibitors
Patel, A. K., & Fonseca, V. A. (2010) · Current Diabetes Reports · doi:10.1007/s11892-010-0095-5 · Cited by 28
N-Chloro-2,2-dimethyltaurines: a new class of remarkably stable N-chlorotaurines
Wang, L., Khosrovi, B., & Najafi, R. (2008) · Tetrahedron Letters · doi:10.1016/j.tetlet.2008.02.038 · Cited by 27
A phase II trial of oral gimatecan for recurrent glioblastoma
Hu, J. L., Wen, P. Y., Abrey, L. E., Fadul, C. E., Drappatz, J., Salem, N., Supko, J. G., & Hochberg, F. H. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-1023-0 · Cited by 26
The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease
Lacaná, E., Yao, L. P., Pariser, A., & Rosenberg, A. S. (2012) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.31316 · Cited by 26
Kim, E., & Shin, W.-H. (2005) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.28.217 · Cited by 25
Cummings, J., Zweifel, M., Smith, N., Ross, P., Peters, J., Rustin, G. J. S., Price, P., Middleton, M. R., Ward, T. H., & Dive, C. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.165 · Cited by 25
Hornsey, M., Phee, L. M., Stubbings, W. J., & Wareham, D. W. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.05.010 · Cited by 25
Yin, M.-B., Hapke, G., Wu, J., Azrak, R. G., Frank, C. L., Wrzosek, C., & Rustum, Y. M. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00683-6 · Cited by 24
Akinaga, S., Ashizawa, T., Gomi, K., Ohno, H., Morimoto, M., Murakata, C., & Okabe, M. (1992) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00685943 · Cited by 24
Ferrari, P., Ferrandi, M., Valentini, G., Manunta, P., & Bianchi, G. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2006.07.058 · Cited by 24
Antibiotics in Phase II and III Clinical Trials
Coates, A. R. M., & Halls, G. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-28951-4_11 · Cited by 23
Shirsath, N., Rathos, M. J., Chaudhari, U., Sivaramakrishnan, H., & Joshi, K. S. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.08.010 · Cited by 23
Ward, D. J., Martino, O. I., Simpson, S., & Stevens, A. J. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-002088 · Cited by 23
Aparicio, L. M. A., Pulido, E. G., & Gallego, G. A. (2011) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32834d237b · Cited by 23
Shin, S. J., Jeung, H., Ahn, J. B., Rha, S. Y., Roh, J. K., Park, K. S., Kim, D. H., Kim, C., & Chung, H. C. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9287-8 · Cited by 22
Bronson, J. J., Dhar, T. G. M., Ewing, W. R., & Lönberg, N. (2011) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-386009-5.00002-3 · Cited by 22
2012 In review - Part I: The year's new drugs and biologics
Graul, A., Lupone, B., Cruces, E., & Stringer, M. (2013) · Drugs of today · doi:10.1358/dot.2013.49.1.1933991 · Cited by 22
Antineoplastic agents. 200. Absolute configuration of the bryostatins
Pettit, G. R., Herald, D. L., Gao, F., Sengupta, D., & Herald, C. L. (1991) · The Journal of Organic Chemistry · doi:10.1021/jo00003a086 · Cited by 21
The Year's New Drugs & Biologics, 2013: Part I
Graul, A., Cruces, E., & Stringer, M. (2014) · Drugs of today · doi:10.1358/dot.2014.50.1.2116673 · Cited by 21
Pautasso, C., Bringhen, S., Cerrato, C., Magarotto, V., & Palumbo, A. P. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.817556 · Cited by 20
Yap, T. A., Cortés-Funes, H., Shaw, H. M., Rodriguez, R., Olmos, D., Lal, R., Fong, P. C. C., Tan, D. S. W., Harris, D. R., Capdevila, J., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.99 · Cited by 20
Scarpace, S. L. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.06.003 · Cited by 19
OASIS-HT: Design of a Pharmacogenomic Dose-Finding Study
Staessen, J. A., Kuznetsova, T., Accetto, R., Bacchieri, A., Brand, E., Burnier, M., Celis, H., Citterio, L., de Leeuw, P. W., Filipovský, J., et al. (2005) · Pharmacogenomics · doi:10.2217/14622416.6.7.755 · Cited by 19
Rimassa, L., Personeni, N., Simonelli, M., & Santoro, A. (2013) · Future Oncology · doi:10.2217/fon.12.188 · Cited by 18
Cited by
Natural products as sources of new drugs from 1981 to 2014
Newman, D. J., & Cragg, G. M. (2016) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5b01055 · Cited by 5,858
Discovery and resupply of pharmacologically active plant-derived natural products: A review
Atanasov, A. G., Waltenberger, B., Pferschy-Wenzig, E.-M., Linder, T., Wawrosch, C., Uhrin, P., Temml, V., Wang, L., Schwaiger, S., Heiss, E. H., et al. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2015.08.001 · Cited by 2,904
Loh, C.-Y., Chai, J., Tang, T., Wong, W., Sethi, G., Shanmugam, M., Chong, P., & Looi, C. (2019) · Cells · doi:10.3390/cells8101118 · Cited by 1,315
Natural product discovery: past, present, and future
Katz, L., & Baltz, R. H. (2016) · Journal of Industrial Microbiology and Biotechnology · doi:10.1007/s10295-015-1723-5 · Cited by 1,144
Anand, U., Jacobo-Herrera, N., Altemimi, A., & Lakhssassi, N. (2019) · Metabolites · doi:10.3390/metabo9110258 · Cited by 867
Metadata
- Authors
- Butler, M. S., Robertson, A. A. B., & Cooper, M. A.
- Venue
- Nat. Prod. Rep.
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2014
- Volume
- 31
- Issue
- 11
- Pages
- 1612-1661
- ISSN
- 0265-0568 (ISSN-L)
- 1460-4752
- OpenAlex
- W2088629793
- Cited by
- 602
- References
- 420
- FWCI
- 36.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.